Research & Clinical Trials
Ladera Medical's FASTEN Trial Shows 0.5-Minute Hemostasis in 55 TAVR Patients
By News Desk ·
Key takeaways
- Ladera Medical's FASTEN trial enrolled 55 TAVR/TAVI patients at six sites in Australia, Belgium and the Netherlands.
- The Ladera Large Bore Closure System achieved 98.1% freedom from major access-site complications at 30 days.
- Mean time to hemostasis was 0.5 minutes, with technical success at 94.5% and treatment success at 94.3%.
Ladera Medical reported full FASTEN trial results showing its Large Bore Closure System achieved a mean time to hemostasis of 0.5 minutes and 98.1% freedom from major access-site complications at 30 days in 55 TAVR/TAVI patients. The Menlo Park, California-based private medtech company presented the data at London Valves 2026, PR Newswire reported on November 22, 2026.
Inside the FASTEN Trial Results
Jan van der Heyden, an interventional cardiologist at St. Jan Hospital in Bruges, Belgium, presented the data in a Late-Breaking Clinical Trials session. FASTEN is a prospective, multicenter, single-arm study that enrolled 55 patients at six sites in Australia, Belgium and the Netherlands. The primary safety endpoint was freedom from major complications of the target-limb access site through 30 days, as adjudicated by an independent clinical events committee.
The study reported freedom from major access-site complications at 30 days of 98.1% (52/53) and freedom from minor access-site complications at 30 days of 98.1% (52/53). Mean time to hemostasis was 0.5 ± 2.0 minutes, with a median of 0 minutes. Technical success was 94.5% (52/55), and treatment success, defined as technical success with freedom from major complications, was 94.3% (50/53). Mean time to ambulation was 14.3 ± 14.5 hours.
"These results show that a suture-based system built for large bore closure can achieve fast, reliable hemostasis with a low rate of major access-site complications at 30 days," van der Heyden said. He added that operators find the device intuitive and that it can be used pre-close or post-close, with guidewire access maintained throughout closure.
The Ladera System is a suture-mediated vascular closure device that deploys two parallel sutures simultaneously. It is designed to close 10F to 24F arteriotomies with a single device, while existing suture devices were designed for small bore punctures and typically require two or more devices per access site. The system is limited by Federal law to investigational use and is not available for sale in any country.
Robert Gooley, Head of Interventional Cardiac Services at Monash Health in Melbourne, Australia, and a leading enroller in FASTEN, said access-site complications remain a persistent risk as TAVI has become routine. "Today we either combine several small-bore suture devices on a very large arteriotomy or use a device that leaves material inside the artery," he said.
Ladera's Device Status
The Ladera Large Bore Closure System remains limited to investigational use, and Ladera Medical said it is not available for sale in any country. More information is available on the company's website.
Companies in this story
- ladera medical · laderamedical.com